Novo Nordisk Is Falling. Compeitition Is a Killer.
Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
BioSpace2d
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, ...
How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 independent food ...
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
manilatimes14d
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...
NJBIZ16d
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...
MarketWatch16d
Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...
Euroinvestor17d
Novo Nordisk-aktien stiger markant: 'Det er mere end blot noget'
Novo Nordisk-aktien stiger markant i tirsdagens aktiehandel og er i skrivende stund oppe med 4,5 pct. Dermed er Novo Nordisk-aktien steget 17 pct. på en uge. »Det er mere end blot ”noget”,« lyder ...
Wall Street Journal17d
Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...
Insider Monkey18d
Here is Why Novo Nordisk A/S (NVO) is Among the Most Oversold Pharma Stocks to Buy According to Analysts
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field ...